Premium
Topical calcipotriol in the treatment of intertriginous psoriasis
Author(s) -
KIENBAUM S.,
LEHMANN P.,
RUZICKA T.
Publication year - 1996
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.1996.d01-1060.x
Subject(s) - calcipotriol , intertriginous , dermatology , psoriasis , medicine , dermatologic agents , chemistry , antibiotics , disease , biochemistry
Summary The purpose of this study was to examine the effectiveness and side‐effects of the vitamin D analogue calcipotriol, applied topically to psoriatic skin lesions in intertriginous areas, in an open and uncontrolled trial. Twelve patients with psoriasis vulgaris who presented with psoriatic lesions in the axilla, and inguinal and anal folds, were treated with calcipotriol ointment (50μg/g) twice daily for 6 weeks. Examination and photographic documentation were performed before treatment, at 3 weeks of treatment, and at 6 weeks of treatment. The mean improvement in the extent and severity of the psoriatic plaques was determined with a semiquantitative grading system closely realted to the psoriasis area and severity index (M‐PASI). Two of 12 patients showed insufficient response to therapy. Five of 12 patients showed a quick response within 3 weeks or less, and five of 12 patients showed a slow response which could be seen only after 6 weeks of treatment. Minimal burning was reported in one patient, slight lesional and/or perilesional irritation in five patients, and, in the remaining, no side‐effects occurred. Topical calcipotriol is an effective and safe treatment for intertriginous psoriasis.